Navigation Links
MSPP Holds Seventh Annual 5K Lucero Memorial Run and Latino Mental Health Breakfast on Sunday, September 28, 2008
Date:9/27/2008

Hundreds to "finish" fallen marathon runner's race and raise funds for

Latino Mental Health Training Program at Massachusetts School of

Professional Psychology

BOSTON, Sept. 27 /PRNewswire-USNewswire/ -- On Sunday, September 28, for the seventh year in a row since her untimely death, hundreds will run or walk to "finish the race" for Dr. Cynthia Lucero, the talented young psychologist who died during the 2002 Boston marathon, at the same time raising funds for her legacy. That legacy is training, through language and cultural immersion, to create culturally sensitive and linguistically competent psychologists (in Spanish) to care for Latinos, the fastest growing segment of the US population.

The race honors the late Dr. Cynthia Lucero, who had devoted her life to helping others through her work and community service; Lucero collapsed from hyponatremia, an electrolyte disturbance of salts in the blood, during the 2002 Boston Marathon. Originally from Ecuador, Lucero completed her doctoral project in psychology the day before the Boston Marathon; she was just 12 days shy of her 28th birthday at her death. This year's Lucero Run will be attended again, as it is every year, by members of her family.

The Dr. Cynthia Lucero Center, founded shortly after her death by MSPP and Dr. Lucero's family and friends, created the Latino Mental Health Training Program as one of its major projects.

More about Lucero is available on the MSPP website at http://mspp.edu/community/lucero-center.asp, and more about the Lucero Run can be found at http://mspp.edu/community/events/lucero-run.asp.

Preceding this year's race at 10:30 a.m., the Massachusetts School of Professional Psychology plans a special breakfast for educational, political and Latino leaders to discuss h
'/>"/>

SOURCE Massachusetts School of Professional Psychology
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Massage Therapy Use Holds Steady, Despite Lagging Economy
2. Prisoner Reentry Facility Holds Dedication Ceremony
3. The American Society for Laser Medicine and Surgery Holds Annual Conference on April 1-5, 2009
4. Depression common among Rwandan youth who head households
5. Mucous breakthrough in mice holds promise for cystic fibrosis
6. Drug Holds Promise Against AIDS
7. Biological marker for Alzheimers holds promise for earlier diagnosis and treatment
8. 150 Years Later House Divided Speech Still Holds Strong Message
9. Children in non-English-speaking households face many health disparities, researcher concludes
10. Renhuang Pharmaceuticals, Inc. Holds Trade Show for Tianma Pills; Signs Letters of Intent
11. SleepQuest Holds Open House
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 1Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 2Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 3NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 1NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 3NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 4